Publications by authors named "A Ariani"
Article Synopsis
- The study investigates treatment options for patients with psoriatic arthritis (PsA) who have not responded to one type of medication, focusing on the effectiveness of two strategies: cycling between TNFi drugs and swapping between TNFi and IL17i drugs.
- It included 122 patients treated with either TNFi or IL17i between January 2016 and January 2022, analyzing their drug retention rates using methods like Kaplan-Meier and Cox regression.
- Results showed that the retention rates were highest for patients who swapped from TNFi to IL17i (58%), compared to cycling TNFi (51%) and swapping from IL17i to TNFi (34%), suggesting that the swap strategy may be more effective for maintaining treatment
Background: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA in treated patients. The purpose of this study was to determine the efficacy of UPA to obtain remission or low disease activity (LDA) in a series of UPA patients in patients with RA after 6 and 12 months of treatment in a real-world setting.
View Article and Find Full Text PDFObjectives: The current knowledge about the role of comorbidities in systemic sclerosis (SSc) is limited. Therefore, the aim of this study was to evaluate the prevalence of comorbidities and their impact on disease activity and prognosis in the Systemic sclerosis PRogression INvestiGation (SPRING) registry.
Methods: SSc patients from the SPRING registry, fulfilling the ACR/EULAR 2013 classification criteria, with complete data on baseline comorbidities were enrolled.
Article Synopsis
- The Janus kinase inhibitors (JAKi) like tofacitinib, baricitinib, upadacitinib, and filgotinib are effective in treating rheumatoid arthritis but faced safety concerns from the FDA and EMA, particularly about serious adverse events (SAEs) such as thrombosis and cancer.
- The study aimed to analyze the impact of the EMA's first two safety warnings on how rheumatologists in Italy prescribed JAKi from July 2019 to June 2022, using data from 29 rheumatology centers.
- Results showed a significant reduction (32%) in JAKi prescriptions after the first warning, with a smaller decrease (16%) observed after the second warning, although there
Background: Oxygen deprivation (OD) is a critical condition that can lead to brain damage and even death. Current hypoxia management approaches are limited in effectiveness. (CA), known for its neuroprotective properties, offers a potential alternative for OD treatment.
View Article and Find Full Text PDF